Patent: 10,485,844
✉ Email this page to a colleague
Summary for Patent: 10,485,844
Title: | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
Abstract: | The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable. |
Inventor(s): | Radin; Allen (New York, NY), Graham; Neil (Croton-on-Hudson, NY), Akinlade; Bolanle (White Plains, NY), Pirozzi; Gianluca (Bridgewater, NJ), Sun; Xing (Bridgewater, NJ), Hultsch; Thomas (Bridgewater, NJ), Shumel; Brad S. (Chappaqua, NY), Bansal; Ashish (White Plains, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR) |
Application Number: | 15/711,815 |
Patent Claims: | see list of patent claims |
Details for Patent 10,485,844
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2037-08-18 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 03/28/2017 | ⤷ Try a Trial | 2037-08-18 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/19/2018 | ⤷ Try a Trial | 2037-08-18 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/18/2020 | ⤷ Try a Trial | 2037-08-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |